HD-P023
- Generic Name
- HD-P023
Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06889350
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06339788
- Locations
- 🇰🇷
Central Hospital, Siheung-si, Gyeonggi-do, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath